Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

NCT04204057 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: Tenalisib

Sponsor

Rhizen Pharmaceuticals SA